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Vector control with long-lasting insecticidal nets (LLINs) and indoor residual spraying are 14 
responsible for more than two thirds of the reduction seen in malaria prevalence in Africa 15 
over the last 15 years (1). Yet the behavioral plasticity of mosquito vectors can lead to 16 
residual transmission and possibly hamper elimination efforts (2, 3).  17 
One identified source of residual transmission is partial zoophagy. Mosquitoes that feed on 18 
peridomestic livestock can avoid contact with insecticides and survive to continue 19 
transmission once human blood is available again (3). This behavioral pattern could be seen 20 
after the scale-up of LLINs that put selective pressure on vectors that bite predominantly 21 
humans indoors (4), either by allowing a shift to a vector species with different behavior (5) 22 
or by selecting members of the same species that circumvent LLINs by biting outdoors (6) or 23 
outside sleeping hours (7). 24 
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Ivermectin is an endectocide, a drug that kills ectoparasites that feed on treated subjects. 25 
Ivermectin mass drug administration to humans has been proposed as a potential 26 
complementary measure to reduce malaria transmission (8). Additional treatment of 27 
peridomestic livestock with ivermectin could reduce malaria transmission by killing partially 28 
zoophagic vectors (9) and also contribute to human wellbeing via the one-health concept, 29 
improving food production and economic benefits of animal owners (10).  30 
Ivermectin, however, has a relatively short half-life (3.5 days in pigs (11) and 2.8 days in 31 
cattle (12)), although veterinary use allows more flexibility in dose and route of 32 
administration. Even novel injectable formulations at 3.15% used at a three-fold dose would 33 
only sustain mosquito-killing concentrations for maximum estimated 40 days in cattle (13). 34 
Consideration should be given to longer-lasting formulations specifically conceived for 35 
vector control.  36 
We previously showed that subcutaneous long-lasting formulations sustained mosquito-37 
killing ivermectin levels in a rabbit model for more than six months (14). Using the same 38 
formulations, we aimed at achieving stable and safe ivermectin levels in a larger mammal, 39 
the pig.  40 
Methods. We chose two 80-kg hybrid mini pigs to facilitate extrapolation to larger 41 
livestock such as cattle. We tested the two formulations of subcutaneous silicone rods that 42 
showed the most promising pharmacokinetic profile in our previous experiment (14). The 43 
rods are 40 mm long and have a 1 mm radius; four or five devices are inserted 44 
subcutaneously in the back or thighs by means of a trocar used for commercially available 45 
hormonal implants. Formulation “F” contains 80% ivermectin (29 mg), 7% sucrose and 13% 46 
deoxycholate. Formulation “X” contains 35% ivermectin (13 mg), 10% sucrose and 55% 47 
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deoxycholate, which greatly increases the elution of the drug (for further details on implant 48 
design refer to (14) ).   49 
Plasma ivermectin levels were measured weekly for 12 weeks after the first month. At 50 
completion of the experiment, the implants were removed and the ivermectin remaining in 51 
the rods quantified. Animals were checked daily for toxicity. The protocol was approved by 52 
the Institutional Animal Care and Use Committee of the University of Navarra. 53 
Results. The implants sustained stable ivermectin plasma levels around 20 ng/ml for 54 
more than 12 weeks (Figure 1), greatly exceeding 6 ng/ml, the concentration needed to kill 55 
50% of Anopheles gambiae mosquitoes in 10 days (15). Both formulations showed a similar 56 
pharmacokinetic pattern, formulation “F” eluted 47% of its ivermectin content while 57 
formulation “X” eluted 55%. The mean daily dose received by the pig with formulation “F” 58 
was 43 mcg/kg/day and for that with formulation “F” 9.8 mcg/kg/day. No clinical adverse 59 
effects were seen in the pigs.  60 
Conclusion. Our results show there is potential to safely sustain mosquitocidal levels 61 
of ivermectin in larger mammals for months using a subcutaneous formulation. Whether an 62 
entomologically relevant outcome can be expected should be tested by means of a cluster 63 
randomized trial. This approach could contribute to human wellbeing not only by reducing 64 
residual malaria transmission driven by zoophagic vectors but also by improving the health 65 
of economically relevant livestock. Hence this intervention could be attractive for livestock 66 
owners, possibly opening the door for previously unforeseen funding collaborations. 67 
 68 
Acknowledgements 69 




Funding information 72 
This work was funded by the University of Navarra. Carlos Chaccour is supported by a 73 
Ramón Areces fellowship. 74 
 75 
References 76 
1. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle KE, 77 
Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briet O, Penny MA, Smith TA, 78 
Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, Lynch M, Lindgren F, 79 
Cohen JM, Murray CL, Smith DL, Hay SI, Cibulskis RE, Gething PW. 2015. 80 
The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 81 
2015. Nature 526:207-211. 82 
2. Durnez LC, Marc 2014. Residual transmission of malaria: an old issue for new 83 
approaches. In Manguin S (ed), Anopheles Mosquitoes – New Insights into Malaria 84 
Vectors. InTech. 85 
3. Killeen GF. 2014. Characterizing, controlling and eliminating residual malaria 86 
transmission. Malar J 13:330. 87 
4. Russell TL, Lwetoijera DW, Maliti D, Chipwaza B, Kihonda J, Charlwood JD, 88 
Smith TA, Lengeler C, Mwanyangala MA, Nathan R, Knols BG, Takken W, 89 
Killeen GF. 2010. Impact of promoting longer-lasting insecticide treatment of bed 90 
nets upon malaria transmission in a rural Tanzanian setting with pre-existing high 91 
coverage of untreated nets. Malar J 9:187. 92 
5. Kitau J, Oxborough RM, Tungu PK, Matowo J, Malima RC, Magesa SM, Bruce 93 
J, Mosha FW, Rowland MW. 2012. Species shifts in the Anopheles gambiae 94 
complex: do LLINs successfully control Anopheles arabiensis? PLoS One 7:e31481. 95 
6. Fornadel CM, Norris LC, Glass GE, Norris DE. 2010. Analysis of Anopheles 96 
arabiensis blood feeding behavior in southern Zambia during the two years after 97 
introduction of insecticide-treated bed nets. Am J Trop Med Hyg 83:848-853. 98 
7. Moiroux N, Gomez MB, Pennetier C, Elanga E, Djenontin A, Chandre F, Djegbe 99 
I, Guis H, Corbel V. 2012. Changes in Anopheles funestus biting behavior following 100 
universal coverage of long-lasting insecticidal nets in Benin. J Infect Dis 206:1622-101 
1629. 102 
8. Chaccour CJ, Kobylinski KC, Bassat Q, Bousema T, Drakeley C, Alonso P, Foy 103 
BD. 2013. Ivermectin to reduce malaria transmission: a research agenda for a 104 
promising new tool for elimination. Malar J 12:153. 105 
9. Pooda HS, Rayaisse JB, Hien DF, Lefevre T, Yerbanga SR, Bengaly Z, Dabire 106 
RK, Belem AM, Sidibe I, Solano P, Mouline K. 2015. Administration of ivermectin 107 
to peridomestic cattle: a promising approach to target the residual transmission of 108 
human malaria. Malar J 13 Suppl 1:496. 109 
10. Rist CL, Garchitorena A, Ngonghala CN, Gillespie TR, Bonds MH. 2015. The 110 
Burden of Livestock Parasites on the Poor. Trends in Parasitology 31 111 
527-530. 112 
11. Lifschitz A, Pis A, Alvarez L, Virkel G, Sanchez S, Sallovitz J, Kujanek R, 113 
Lanusse C. 1999. Bioequivalence of ivermectin formulations in pigs and cattle. J Vet 114 
Pharmacol Ther 22:27-34. 115 
5 
 
12. Ndong TB, Kane Y, Ba MA, Sane I, Sutra JF, Alvinerie M. 2005. 116 
Pharmacokinetics of ivermectin in zebu Gobra (Bos indicus). Vet Parasitol 128:169-117 
173. 118 
13. Lifschitz A, Virkel G, Ballent M, Sallovitz J, Imperiale F, Pis A, Lanusse C. 119 
2007. Ivermectin (3.15%) long-acting formulations in cattle: absorption pattern and 120 
pharmacokinetic considerations. Vet Parasitol 147:303-310. 121 
14. Chaccour C, Irigoyen A, Gil A, Martinez D, Slater H, Hammann F, Del Pozo J. 122 
2015. Screening for an ivermectin slow-release formulation suitable for malaria 123 
vector control. Malar J 14:102. 124 
15. Ouedraogo AL, Bastiaens GJ, Tiono AB, Guelbeogo WM, Kobylinski KC, 125 
Ouedraogo A, Barry A, Bougouma EC, Nebie I, Ouattara MS, Lanke KH, 126 
Fleckenstein L, Sauerwein RW, Slater HC, Churcher TS, Sirima SB, Drakeley 127 
C, Bousema T. 2015. Efficacy and safety of the mosquitocidal drug ivermectin to 128 
prevent malaria transmission after treatment: a double-blind, randomized, clinical 129 
trial. Clin Infect Dis 60:357-365. 130 
 131 
Legend  132 
FIG. 1. Ivermectin plasma levels after implantation of a slow release formulation in two 133 
80 kg-pigs. Levels above the 10-day lethal concentration 50 for An. gambiae (double blue 134 
line) are sustained for at least 12 weeks. We expect this effect to last for at least 6 months 135 
given that the implants still contained 45-53% of ivermectin after removal at 12 weeks. The 136 
dotted lines are included for comparison; red reflects the approximate PK of a single 137 
subcutaneous 300 mcg/kg dose of 1% ivermectin in pigs (11), orange reflects the 138 
approximate PK of a single subcutaneous 630 mcg/kg dose of 3.15% ivermectin in cattle 139 
(13). 140 

